Cargando…

Use of ethinylestradiol/drospirenone combination in patients with the polycystic ovary syndrome

Polycystic ovary syndrome (PCOS) is one of the most common endocrine/metabolic disorders found in women, affecting approximately 105 million women worldwide. It is characterized by ovulatory dysfunction, often presenting as oligomenorrhea or amenorrhea and either clinical or biochemical hyperandroge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mathur, Ruchi, Levin, Olga, Azziz, Ricardo
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2008
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504056/ https://www.ncbi.nlm.nih.gov/pubmed/18728832

Ejemplares similares

Ethinylestradiol(30μg)-drospirenone and metformin: could this combination improve endothelial dysfunction in polycystic ovary syndrome?
por: Ilie, Ioana Rada, et al.
Publicado: (2012)

Pharmacokinetics of drospirenone and ethinylestradiol in Caucasian and Japanese women
por: Blode, Hartmut, et al.
Publicado: (2012)

Evaluation of Apelin and Insulin Resistance in Patients with PCOS and Therapeutic Effect of Drospirenone-Ethinylestradiol Plus Metformin
por: Sun, Xianchang, et al.
Publicado: (2015)

Effect and safety of drospirenone and ethinylestradiol tablets (II) for dysmenorrhea: A systematic review and meta-analysis
por: Shi, Jinghua, et al.
Publicado: (2022)

Bleeding Pattern and Management of Unexpected Bleeding/Spotting with an Extended Regimen of a Combination of Ethinylestradiol 20 mcg and Drospirenone 3 mg
por: Bonassi Machado, Rogerio, et al.
Publicado: (2020)

The polycystic ovary syndrome: the first 150 years of study
por: Adashi, Eli Y., et al.
Publicado: (2022)

Comparison of the Effects of Hysteroscopic Cold Broad Sword Play Combined with Estrogen and Progestin Sequential Therapy and Drospirenone and Ethinylestradiol Tablets in Patients with Severe Intrauterine Adhesion
por: Zhou, Liping, et al.
Publicado: (2022)

The Efficacy of the Yasmin[Ethinylestradiol-Drospirenone (0.03/3 mg)] Treatment for Postoperative Abortion: A Protocol of Meta-Analysis
por: Tian, Tian, et al.
Publicado: (2022)

Characterisation of the pharmacokinetics of ethinylestradiol and drospirenone in extended-cycle regimens: population pharmacokinetic analysis from a randomised Phase III study
por: Reif, Stefanie, et al.
Publicado: (2013)

Hormone withdrawal-associated symptoms with ethinylestradiol 20 μg/drospirenone 3 mg (24/4 regimen) versus ethinylestradiol 20 μg/desogestrel 150 μg (21/7 regimen)
por: Bitzer, Johannes, et al.
Publicado: (2015)

Burden of Menstrual Pain Measured by Heatmap Visualization of Daily Patient-Reported Data in Japanese Patients Treated with Ethinylestradiol/Drospirenone: A Randomized Controlled Study
por: Momoeda, Mikio, et al.
Publicado: (2020)

Quality of Life in Japanese Patients with Dysmenorrhea Treated with Ethinylestradiol 20 μg/Drospirenone 3 mg in a Real-World Setting: An Observational Study
por: Momoeda, Mikio, et al.
Publicado: (2020)

First Evidence of Genetic Association Between AKT2 and Polycystic Ovary Syndrome
por: Goodarzi, Mark O., et al.
Publicado: (2008)

SAT370 Economic Burden of Endometrial Cancer Associated with Polycystic Ovary Syndrome
por: Pace, Lauren Arielle, et al.
Publicado: (2023)

Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders: A Prospective Randomized Control Trial
por: Wang, Qiu-Yi, et al.
Publicado: (2016)

Efficacy and safety of a flexible extended regimen of ethinylestradiol/drospirenone for the treatment of dysmenorrhea: a multicenter, randomized, open-label, active-controlled study
por: Momoeda, Mikio, et al.
Publicado: (2017)

Neuroendocrine Determinants of Polycystic Ovary Syndrome
por: Szeliga, Anna, et al.
Publicado: (2022)

Does the presence of coexisting diseases modulate the effectiveness of a low-dose estrogen/progestin, ethinylestradiol/drospirenone combination tablet in dysmenorrhea? Reanalysis of two randomized studies in Japanese women
por: Momoeda, Mikio, et al.
Publicado: (2014)

Contraceptive efficacy and tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study
por: Klipping, Christine, et al.
Publicado: (2012)

Drospirenone and mood
por: Zuschmann, Andrew
Publicado: (2022)

Polycystic Ovary Syndrome in Adolescence
por: Deans, Rebecca
Publicado: (2019)

Complex diseases and co-morbidities: polycystic ovary syndrome and type 2 diabetes mellitus
por: Rodgers, Raymond J, et al.
Publicado: (2019)

Long-term tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study
por: Klipping, Christine, et al.
Publicado: (2012)

Pregnancy in polycystic ovary syndrome
por: Kamalanathan, Sadishkumar, et al.
Publicado: (2013)

Update on polycystic ovary syndrome
por: Kim, Jin Ju
Publicado: (2021)

Hormonal and Metabolic Factors Influence the Action of Progesterone on the Endometrium of Women with Polycystic Ovary Syndrome
por: Baracat, Maria Candida P., et al.
Publicado: (2023)

THU636 Prevalence Of Metabolic Syndrome In A Sample Of Hispanic Patients With Polycystic Ovary Syndrome
por: Arroyo, Isabel C, et al.
Publicado: (2023)

Risks for Gestational Diabetes Mellitus and Pregnancy-Induced Hypertension Are Increased in Polycystic Ovary Syndrome
por: Wang, Yunhui, et al.
Publicado: (2013)

Quality of Life in Japanese Patients with Dysmenorrhea or Endometriosis-Associated Pelvic Pain Treated with Extended Regimen Ethinylestradiol/Drospirenone in a Real-World Setting: A Prospective Observational Study
por: Yoshino, Osamu, et al.
Publicado: (2022)

Treatment options for polycystic ovary syndrome
por: Badawy, Ahmed, et al.
Publicado: (2011)

Features of Polycystic Ovary Syndrome in adolescence
por: Tsikouras, P, et al.
Publicado: (2015)

Dyslipidemia in women with polycystic ovary syndrome
por: Kim, Jin Ju, et al.
Publicado: (2013)

Cardiometabolic risk in polycystic ovary syndrome
por: Bajuk Studen, Katica, et al.
Publicado: (2018)

Polycystic ovary syndrome and mitochondrial dysfunction
por: Zhang, Jingshun, et al.
Publicado: (2019)

Polycystic Ovary Syndrome and Gender Identity
por: Liu, Minghao, et al.
Publicado: (2020)

Estrogen Receptors in Polycystic Ovary Syndrome
por: Xu, Xue-Ling, et al.
Publicado: (2021)

Dietary supplements for polycystic ovary syndrome
por: KIANI, AYSHA KARIM, et al.
Publicado: (2022)

Harnessing Expression Data to Identify Novel Candidate Genes in Polycystic Ovary Syndrome
por: Jones, Michelle R., et al.
Publicado: (2011)

SAT388 Does Obesity Drive the Development of Polycystic Ovary Syndrome (PCOS)? An Epidemiologic Study
por: Amiri, Mina, et al.
Publicado: (2023)

Effects of metformin use in pregnant patients with polycystic ovary syndrome
por: Kumar, Pratap, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ltupklavio9aer1foddspsp5ln